Last reviewed · How we verify
CC-220
CC-220 is a small molecule that modulates the activity of cereblon, an E3 ubiquitin ligase, leading to the degradation of specific proteins involved in inflammation and immune responses.
CC-220 is a small molecule that modulates the activity of cereblon, an E3 ubiquitin ligase, leading to the degradation of specific proteins involved in inflammation and immune responses. Used for Systemic lupus erythematosus, Multiple myeloma.
At a glance
| Generic name | CC-220 |
|---|---|
| Also known as | Iberdomide, BMS-986382 |
| Sponsor | Celgene |
| Drug class | cereblon modulator |
| Target | cereblon |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to cereblon, CC-220 enhances the degradation of Ikaros and Aiolos, transcription factors that play a role in B-cell and T-cell function, thereby reducing their activity and dampening immune responses associated with autoimmune diseases.
Approved indications
- Systemic lupus erythematosus
- Multiple myeloma
Common side effects
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (PHASE1, PHASE2)
- Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma (PHASE2)
- Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma (PHASE1)
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (PHASE1)
- Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (PHASE1, PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1)
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC-220 CI brief — competitive landscape report
- CC-220 updates RSS · CI watch RSS
- Celgene portfolio CI